Glaukos Future Growth

Future criteria checks 1/6

Glaukos is forecast to grow earnings and revenue by 49.1% and 17.6% per annum respectively. EPS is expected to grow by 44.2% per annum. Return on equity is forecast to be 1.2% in 3 years.

Key information

49.1%

Earnings growth rate

44.2%

EPS growth rate

Medical Equipment earnings growth16.2%
Revenue growth rate17.6%
Future return on equity1.2%
Analyst coverage

Good

Last updated24 Apr 2024

Recent future growth updates

Recent updates

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Apr 22
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Apr 04
Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21
Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20
Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19
Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside

Jul 12

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Mar 14
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Nov 29
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Aug 15
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Earnings and Revenue Growth Forecasts

NYSE:GKOS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026561-55-2119310
12/31/2025445-74-723815
12/31/2024357-113-39-1915
12/31/2023315-135-78-58N/A
9/30/2023304-129-75-51N/A
6/30/2023297-126-97-70N/A
3/31/2023289-139-104-74N/A
12/31/2022283-99-63-33N/A
9/30/2022285-90-65-34N/A
6/30/2022288-56-2511N/A
3/31/2022294-28-730N/A
12/31/2021294-50-2325N/A
9/30/2021294-38-140N/A
6/30/2021284-60-1913N/A
3/31/2021238-83-29-6N/A
12/31/2020225-120-30-23N/A
9/30/2020218-73-44-38N/A
6/30/2020211-71-37-31N/A
3/31/2020238-37-19-14N/A
12/31/201923715-50N/A
9/30/2019225-191021N/A
6/30/2019211-121728N/A
3/31/2019195-121626N/A
12/31/2018181-13919N/A
9/30/2018169-141014N/A
6/30/2018165-61117N/A
3/31/2018163-41117N/A
12/31/201715902026N/A
9/30/2017151-1N/A17N/A
6/30/2017140-1N/A14N/A
3/31/20171275N/A16N/A
12/31/20161145N/A12N/A
9/30/20161022N/A8N/A
6/30/201691-1N/A4N/A
3/31/201680-35N/A-2N/A
12/31/201572-37N/A-2N/A
9/30/201566-40N/A-3N/A
6/30/201559-39N/A-2N/A
3/31/201552-9N/A-3N/A
12/31/201446-12N/A-7N/A
9/30/201438-11N/A-8N/A
6/30/201433-12N/A-10N/A
3/31/201426-13N/A-13N/A
12/31/201321-13N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GKOS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GKOS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GKOS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GKOS's revenue (17.6% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: GKOS's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GKOS's Return on Equity is forecast to be low in 3 years time (1.2%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.